{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T16:34:53Z","timestamp":1781195693659,"version":"3.54.1"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>A case report highlights the challenges faced in managing a 66-year-old Chinese woman diagnosed with anti-MDA5 antibody-positive dermatomyositis (MDA5-DM) complicated by rapidly progressive interstitial lung disease (RP-ILD). Despite aggressive therapeutic interventions, her condition rapidly deteriorated, emphasizing the severity and devastating nature of this subtype of DM. A salient feature of her clinical presentation was the marked elevation of interferon (IFN)-\u03b3 and IFN-\u03b1 levels, underscoring the pivotal role that IFNs play in driving the pathogenesis and progression of MDA5-DM-related RP-ILD. In an attempt to stem the relentless progression, tofacitinib, a Janus kinase (JAK) inhibitor, was applied into her treatment regimen. This therapeutic intervention led to a transient decrease in IFN-related cytokines, offering a glimpse of hope that JAK inhibition could modulate the exaggerated IFN response implicated in the disease. Other four similar cases underscore the critical importance of early and aggressive intervention in MDA5-DM patients, as well as the potential therapeutic avenues involving IFN blockers by JAK inhibitors. Urgent and well-designed clinical trials are imperative to unravel the intricate interplay between RP-ILD and the IFN signature in MDA5-DM, and to evaluate novel therapeutic targets that promise long-term efficacy and safety.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1515602","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T06:34:50Z","timestamp":1738650890000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case report: Exploring efficacy of tofacitinib in modulating interferon response in five case of anti-MDA5+ dermatomyositis with interstitial lung disease"],"prefix":"10.3389","volume":"16","author":[{"given":"Jie","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keliang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41584-023-01054-9","article-title":"Anti-MDA5 antibody-positive dermatomyositis: pathogenesis and clinical progress","volume":"1","author":"Xin","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/nejmc1900045","article-title":"Tofacitinib in amyopathic dermatomyositis\u2013associated interstitial lung disease","volume":"381","author":"Chen","year":"2019","journal-title":"New Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/rhu.0000000000002010","article-title":"Efficacy and safety of tofacitinib in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis","volume":"29","author":"Li","year":"2023","journal-title":"J Clin Rheumatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"6458","DOI":"10.1038\/s41467-022-34145-4","article-title":"Single-cell profiling reveals distinct adaptive immune hallmarks in MDA5+ dermatomyositis with therapeutic implications","volume":"13","author":"Ye","year":"2022","journal-title":"Nat Commun"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab371","article-title":"Antiviral proinflammatory phenotype of monocytes in anti-MDA5 antibody-associated interstitial lung disease","volume":"61","author":"Gono","year":"2022","journal-title":"Rheumatology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.628128","article-title":"Aberrantly expressed galectin-9 is involved in the immunopathogenesis of anti-MDA5-positive dermatomyositis-associated interstitial lung disease","volume":"9","author":"Liang","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0466-2","article-title":"Interferon target-gene expression and epigenomic signatures in health and disease","volume":"20","author":"Franck","year":"2019","journal-title":"Nat Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.833114","article-title":"Pathogenesis of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis: A concise review with an emphasis on type I interferon system","volume":"24","author":"Huifang","year":"2022","journal-title":"Front Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001202","article-title":"Seasonal and Residential Clustering at Disease Onset of anti-MDA5-associated Interstitial Lung Disease","volume":"6","author":"Nishina","year":"2020","journal-title":"RMD Open"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm-conference.2023.207.1_meetingabstracts.a1446","article-title":"Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease","volume":"50","author":"Romero-Bueno","year":"2020","journal-title":"Semin Arthritis Rheumatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key188","article-title":"Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis","volume":"57","author":"Kurasawa","year":"2018","journal-title":"Rheumatology"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002795","article-title":"Efficacy and safety of dose escalation of tofacitinib in refractory anti-MDA5 antibody-positive dermatomyositis","volume":"9","author":"Ida","year":"2023","journal-title":"RMD Open"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000009727","article-title":"Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: Study of 121 cases","volume":"95","author":"Allenbach","year":"2020","journal-title":"Neurology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/art.42308","article-title":"Identification of three different phenotypes in anti\u2013melanoma differentiation associated gene 5 antibody-positive dermatomyositis patients: implications for prediction of rapidly progressive interstitial lung disease","volume":"75","author":"Xu","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/df2oc3","article-title":"Anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis exhibit three clinical phenotypes with different prognoses","volume":"40","author":"Yang","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"B16","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/ar2883","article-title":"Genetic associations in type I interferon related pathways with\nautoimmunity","volume":"12","author":"Delgado-Vega","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.166242","article-title":"MDA5 RNA-sensing pathway activation by Mycobacterium tuberculosis promotes innate immune subversion and pathogen survival","volume":"8","author":"Korin B","year":"2023","journal-title":"JCI Insight"},{"key":"B18","doi-asserted-by":"publisher","first-page":"105136","DOI":"10.2139\/ssrn.4624350","article-title":"MDA5-autoimmunity and interstitial pneumonitis contemporaneous with the COVID-19 pandemic (MIP-C)","volume":"104","author":"David","year":"2024","journal-title":"eBioMedicine"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/art.41105","article-title":"Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis","volume":"72","author":"Tsuji","year":"2020","journal-title":"Arthritis Rheumatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1515602\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T06:34:53Z","timestamp":1738650893000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1515602\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,4]]},"references-count":19,"alternative-id":["10.3389\/fimmu.2025.1515602"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1515602","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,4]]},"article-number":"1515602"}}